Product Information
POTASSIUM CL ER 8 MEQ TABLET is a generic product labeled by Aurobindo Pharma Limited, priced at $0.1028 per EA under NDC 65862098601. Its NADAC has been published 344 times since Mar 4, 2020.
FDA first approved this application on Dec 19, 2018. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
600 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
65862098601
Classification
Generic
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
POTASSIUM CHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA210921FDA Approved
12/19/2018
TE Code
AB2
On Market Since
12/19/2018
Pharmacological Classes
Price Statistics
The NADAC for POTASSIUM CL ER 8 MEQ TABLET has been published 344 times since Mar 4, 2020, and over the history we have for it it has declined 55.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1028 per EA |
|---|---|
| All-time high | $0.2329 (Mar 11, 2020) |
| All-time low | $0.1020 (Aug 19, 2026) |
| 52-week high | $0.1411 |
| 52-week low | $0.1020 |
| Median price | $0.1430 |
| Average price | $0.1553 |
| Largest weekly change | -39.3% (Apr 17, 2024) |
| Weeks tracked | 344 |
| Tracking since | Mar 4, 2020 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Potassium Chloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Osmotic Laxative class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of POTASSIUM CL ER 8 MEQ TABLET?
The current National Average Drug Acquisition Cost (NADAC) for POTASSIUM CL ER 8 MEQ TABLET, manufactured by Aurobindo Pharma Limited, is $0.1028 per EA (NDC 65862098601), effective Sep 30, 2026.
How has the price of POTASSIUM CL ER 8 MEQ TABLET changed over time?
Over the history we have for it, the NADAC for POTASSIUM CL ER 8 MEQ TABLET has declined 55.9%. It has been tracked across 344 weekly CMS publications since Mar 4, 2020.
What are the highest and lowest recorded NADAC prices for POTASSIUM CL ER 8 MEQ TABLET?
Since Mar 4, 2020, the NADAC for POTASSIUM CL ER 8 MEQ TABLET has ranged from a low of $0.1020 (Aug 19, 2026) to a high of $0.2329 (Mar 11, 2020), with a median of $0.1430 per EA.
Are there cheaper alternatives to POTASSIUM CL ER 8 MEQ TABLET?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as POTASSIUM CL ER 8 MEQ TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures POTASSIUM CL ER 8 MEQ TABLET?
POTASSIUM CL ER 8 MEQ TABLET (NDC 65862098601) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.